Literature DB >> 25100123

Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition.

Yu Lu1, Chen Liu, Yong-Feng Xu, He Cheng, Si Shi, Chun-Tao Wu, Xian-Jun Yu.   

Abstract

BACKGROUND: Stathmin is a ubiquitous cytosolic regulatory phosphoprotein and is overexpressed in different human malignancies. The main physiological function of stathmin is to interfere with microtubule dynamics by promoting depolymerization of microtubules or by preventing polymerization of tubulin heterodimers. Stathmin plays important roles in regulating many cellular functions as a result of its microtubule-destabilizing activity. Currently, the critical roles of stathmin in cancer cells, as well as in lymphocytes have been valued. This review discusses stathmin and microtubule dynamics in cancer development, and hypothesizes their possible relationship with epithelial-mesenchymal transition (EMT). DATA SOURCES: A PubMed search using such terms as "stathmin", "microtubule dynamics", "epithelial-mesenchymal transition", "EMT", "malignant potential" and "cancer" was performed to identify relevant studies published in English. More than 100 related articles were reviewed.
RESULTS: The literature clearly documented the relationship between stathmin and its microtubule-destabilizing activity of cancer development. However, the particular mechanism is poorly understood. Microtubule disruption is essential for EMT, which is a crucial process during cancer development. As a microtubule-destabilizing protein, stathmin may promote malignant potential in cancer cells by initiating EMT.
CONCLUSIONS: We propose that there is a stathmin-microtubule dynamics-EMT (S-M-E) axis during cancer development. By this axis, stathmin together with its microtubule-destabilizing activity contributes to EMT, which stimulates the malignant potential in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25100123     DOI: 10.1016/s1499-3872(14)60038-2

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  13 in total

1.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection.

Authors:  Mehdi Bouhaddou; Danish Memon; Bjoern Meyer; Kris M White; Veronica V Rezelj; Miguel Correa Marrero; Benjamin J Polacco; James E Melnyk; Svenja Ulferts; Robyn M Kaake; Jyoti Batra; Alicia L Richards; Erica Stevenson; David E Gordon; Ajda Rojc; Kirsten Obernier; Jacqueline M Fabius; Margaret Soucheray; Lisa Miorin; Elena Moreno; Cassandra Koh; Quang Dinh Tran; Alexandra Hardy; Rémy Robinot; Thomas Vallet; Benjamin E Nilsson-Payant; Claudia Hernandez-Armenta; Alistair Dunham; Sebastian Weigang; Julian Knerr; Maya Modak; Diego Quintero; Yuan Zhou; Aurelien Dugourd; Alberto Valdeolivas; Trupti Patil; Qiongyu Li; Ruth Hüttenhain; Merve Cakir; Monita Muralidharan; Minkyu Kim; Gwendolyn Jang; Beril Tutuncuoglu; Joseph Hiatt; Jeffrey Z Guo; Jiewei Xu; Sophia Bouhaddou; Christopher J P Mathy; Anna Gaulton; Emma J Manners; Eloy Félix; Ying Shi; Marisa Goff; Jean K Lim; Timothy McBride; Michael C O'Neal; Yiming Cai; Jason C J Chang; David J Broadhurst; Saker Klippsten; Emmie De Wit; Andrew R Leach; Tanja Kortemme; Brian Shoichet; Melanie Ott; Julio Saez-Rodriguez; Benjamin R tenOever; R Dyche Mullins; Elizabeth R Fischer; Georg Kochs; Robert Grosse; Adolfo García-Sastre; Marco Vignuzzi; Jeffery R Johnson; Kevan M Shokat; Danielle L Swaney; Pedro Beltrao; Nevan J Krogan
Journal:  Cell       Date:  2020-06-28       Impact factor: 41.582

2.  RNA interference-mediated knockdown of SIRT1 and/or SIRT2 in melanoma: Identification of downstream targets by large-scale proteomics analysis.

Authors:  Melissa J Wilking-Busch; Mary A Ndiaye; Xiaoqi Liu; Nihal Ahmad
Journal:  J Proteomics       Date:  2017-09-05       Impact factor: 4.044

3.  Polarity Reversal by Centrosome Repositioning Primes Cell Scattering during Epithelial-to-Mesenchymal Transition.

Authors:  Mithila Burute; Magali Prioux; Guillaume Blin; Sandrine Truchet; Gaëlle Letort; Qingzong Tseng; Thomas Bessy; Sally Lowell; Joanne Young; Odile Filhol; Manuel Théry
Journal:  Dev Cell       Date:  2016-12-29       Impact factor: 12.270

4.  PIWIL1 destabilizes microtubule by suppressing phosphorylation at Ser16 and RLIM-mediated degradation of Stathmin1.

Authors:  Chao Li; Xiaoyan Zhou; Jianhui Chen; Yilu Lu; Qianqian Sun; Dachang Tao; Wei Hu; Xulei Zheng; Shasha Bian; Yunqiang Liu; Yongxin Ma
Journal:  Oncotarget       Date:  2015-09-29

5.  Stathmin1 overexpression in hypopharyngeal squamous cell carcinoma: A new promoter in FaDu cell proliferation and migration.

Authors:  Yan Chen; Qicheng Zhang; Chuanjin Ding; Xiaobo Zhang; Xiaoxia Qiu; Zhenxin Zhang
Journal:  Int J Oncol       Date:  2016-11-23       Impact factor: 5.650

6.  CARMA3 Transcriptional Regulation of STMN1 by NF-κB Promotes Renal Cell Carcinoma Proliferation and Invasion.

Authors:  Du Shi; Zhe Zhang; Chuize Kong
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

7.  Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma.

Authors:  Yongchao Cai; Yong Fu; Changcheng Liu; Xicheng Wang; Pu You; Xiuhua Li; Yanxiang Song; Xiaolan Mu; Ting Fang; Yang Yang; Yuying Gu; Haibin Zhang; Zhiying He
Journal:  Cell Death Dis       Date:  2022-02-24       Impact factor: 8.469

8.  Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway.

Authors:  Fengbo Tan; Hong Zhu; Yiming Tao; Nanhui Yu; Qian Pei; Heli Liu; Yuan Zhou; Haifan Xu; Xiangping Song; Yuqiang Li; Zhongyi Zhou; Xiao He; Xingwen Zhang; Haiping Pei
Journal:  J Exp Clin Cancer Res       Date:  2015-10-09

Review 9.  Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments.

Authors:  Rong Biaoxue; Cai Xiguang; Liu Hua; Yang Shuanying
Journal:  J Transl Med       Date:  2016-09-27       Impact factor: 5.531

10.  Stathmin 1 Induces Murine Hepatocyte Proliferation and Increased Liver Mass.

Authors:  Enpeng Zhao; Yang Shen; Muhammad Amir; Alton B Farris; Mark J Czaja
Journal:  Hepatol Commun       Date:  2019-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.